{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:40:54Z","timestamp":1770993654544,"version":"3.50.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.bcp.2009.05.018","type":"journal-article","created":{"date-parts":[[2009,5,28]],"date-time":"2009-05-28T04:49:17Z","timestamp":1243486157000},"page":"933-940","source":"Crossref","is-referenced-by-count":47,"title":["The biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and reality"],"prefix":"10.1016","volume":"78","author":[{"given":"Zaid","family":"Abassi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Winaver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giora Z.","family":"Feuerstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2009.05.018_bib1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","article-title":"Renin-angiotensin system revisited","volume":"264","author":"Fyhrquist","year":"2008","journal-title":"J Intern Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00004872-200205000-00004","article-title":"Angiotensin I. Angiotensin II and their biologically active peptides","volume":"20","author":"Ferrario","year":"2002","journal-title":"J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1210\/er.2003-0001","article-title":"Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation","volume":"24","author":"Carey","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bcp.2009.05.018_bib4","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"key":"10.1016\/j.bcp.2009.05.018_bib5","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bcp.2009.05.018_bib6","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2009.05.018_bib7","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1111\/j.1440-1681.1998.tb02304.x","article-title":"Haemorphin peptides may be endogenous ligands for brain angiotensin AT4 receptors","volume":"25","author":"Moeller","year":"1998","journal-title":"Clin Exp Pharmacol Physiol Suppl"},{"key":"10.1016\/j.bcp.2009.05.018_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1113\/expphysiol.2008.042002","article-title":"Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis","volume":"93","author":"Santos","year":"2008","journal-title":"Exp Physiol"},{"key":"10.1016\/j.bcp.2009.05.018_bib9","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/ki.1996.511","article-title":"Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen","volume":"50","author":"Nguyen","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2009.05.018_bib10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"109","author":"Nguyen","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2009.05.018_bib11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.ki.5000265","article-title":"Renin\/prorenin receptors","volume":"69","author":"Nguyen","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2009.05.018_bib12","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/ndt\/gfl846","article-title":"Prorenin and the (pro)renin receptor\u2014an update","volume":"22","author":"Jan Danser","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bcp.2009.05.018_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00041552-200301000-00009","article-title":"The renin receptor: the facts, the promise and the hope","volume":"12","author":"Nguyen","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","article-title":"Renin inhibition: what are the therapeutic opportunities?","volume":"16","author":"Fisher","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2009.05.018_bib15","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/HYPERTENSIONAHA.107.101444","article-title":"Prorenin and renin-induced extracellular signal-regulated kinase 1\/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide","volume":"51","author":"Feldt","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/01.HYP.0000215838.48170.0b","article-title":"Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension","volume":"47","author":"Ichihara","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.ki.5000011","article-title":"Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms","volume":"69","author":"Huang","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2009.05.018_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejphar.2008.02.092","article-title":"The (pro)renin receptor: a new addition to the renin-angiotensin system?","volume":"585","author":"Batenburg","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.018_bib19","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2009.05.018_bib20","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(99)10365-9","article-title":"Angiotensin II receptor antagonists","volume":"355","author":"Burnier","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2009.05.018_bib23","first-page":"419","article-title":"Prothrombotic effects of angiotensin","volume":"45","author":"Brown","year":"2000","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib24","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin\u2013angiotensin\u2013aldosterone system and progression of renal disease","volume":"17","author":"Ruster","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2009.05.018_bib25","doi-asserted-by":"crossref","first-page":"1L","DOI":"10.1016\/S0002-9149(01)01878-1","article-title":"The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data","volume":"88","author":"Dzau","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.bcp.2009.05.018_bib26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2009.05.018_bib27","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/00004872-200105000-00001","article-title":"Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift","volume":"19","author":"Epstein","year":"2001","journal-title":"J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib28","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2169\/internalmedicine.40.573","article-title":"Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives","volume":"40","author":"Epstein","year":"2001","journal-title":"Intern Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis","volume":"12","author":"Sato","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","article-title":"Pathophysiological effects of aldosterone in cardiovascular tissues","volume":"12","author":"Rocha","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bcp.2009.05.018_bib31","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2003-030490","article-title":"50th anniversary of aldosterone","volume":"88","author":"Williams","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bcp.2009.05.018_bib32","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2009.05.018_bib33","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archinte.165.12.1410","article-title":"Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials","volume":"165","author":"Turnbull","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2009.05.018_bib35","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib36","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.hjh.0000234122.55895.5b","article-title":"Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial","volume":"24","author":"Kjeldsen","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000236119.96301.f2","article-title":"The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy","volume":"48","author":"Julius","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib38","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1161\/01.CIR.0000131449.94713.AD","article-title":"Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists","volume":"109","author":"Azizi","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2009.05.018_bib39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.HYP.25.1.37","article-title":"Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin\u2013angiotensin\u2013aldosterone system in hypertensive patients","volume":"25","author":"Goldberg","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib40","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1093\/ndt\/gfm363","article-title":"Direct renin inhibitors: the dawn of a new era, or just a variation on a theme?","volume":"22","author":"Segall","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bcp.2009.05.018_bib41","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/01.HYP.32.3.387","article-title":"Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system","volume":"32","author":"Hollenberg","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib42","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(06)69442-7","article-title":"Oral renin inhibitors","volume":"368","author":"Staessen","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2009.05.018_bib43","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)70151-3","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2009.05.018_bib45","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.HYP.0000103630.72812.10","article-title":"Hypertension treatment and control in five European countries, Canada, and the United States","volume":"43","author":"Wolf-Maier","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib47","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1097\/00004872-200309000-00001","article-title":"New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension","volume":"21","author":"Sleight","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib48","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bcp.2009.05.018_bib49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/00004872-200502000-00025","article-title":"Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats","volume":"23","author":"Wood","year":"2005","journal-title":"J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib50","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.amjmed.2007.11.016","article-title":"Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug","volume":"121","author":"Shafiq","year":"2008","journal-title":"Am J Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib51","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2006.11.032","article-title":"Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension","volume":"49","author":"Oh","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bcp.2009.05.018_bib52","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00109-008-0338-y","article-title":"Renin inhibitors, clinical experience","volume":"86","author":"Westermann","year":"2008","journal-title":"J Mol Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.coph.2008.01.003","article-title":"Current concepts: renin inhibition in the treatment of hypertension","volume":"8","author":"Gradman","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.018_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2550","article-title":"Aliskiren: the first renin inhibitor for clinical treatment","volume":"7","author":"Jensen","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2009.05.018_bib55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.ki.5002732","article-title":"Antihypertensive therapy with aliskiren","volume":"73","author":"Luft","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2009.05.018_bib56","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.amjhyper.2007.04.001","article-title":"Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness","volume":"20","author":"Sealey","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/01.CIR.92.4.825","article-title":"Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives","volume":"92","author":"Azizi","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2009.05.018_bib58","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.hjh.0000202812.72341.99","article-title":"Renin inhibition with aliskiren: where are we now, and where are we going?","volume":"24","author":"Azizi","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.bcp.2009.05.018_bib59","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(07)61124-6","article-title":"Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial","volume":"370","author":"Oparil","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2009.05.018_bib60","first-page":"984","article-title":"Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice","volume":"118","author":"Lu","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bcp.2009.05.018_bib61","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1093\/ndt\/gfn184","article-title":"Renin inhibition and atherosclerosis","volume":"23","author":"Luft","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bcp.2009.05.018_bib62","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/HYPERTENSIONAHA.108.114488","article-title":"Aliskiren improves nitric oxide bioavailability and limits atherosclerosis","volume":"52","author":"Verma","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib63","first-page":"CD007066","article-title":"Blood pressure lowering efficacy of renin inhibitors for primary hypertension","author":"Musini","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bcp.2009.05.018_bib64","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1053\/j.ajkd.2008.11.021","article-title":"Dual blockade of the renin-angiotensin system for cardiorenal protection: an update","volume":"53","author":"Arici","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bcp.2009.05.018_bib65","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/ncpneph0298","article-title":"Hypertension and antihypertensive treatment of diabetic nephropathy","volume":"2","author":"Ritz","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.bcp.2009.05.018_bib66","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S1043-2760(03)00111-5","article-title":"The intrarenal renin-angiotensin system and diabetic nephropathy","volume":"14","author":"Carey","year":"2003","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.bcp.2009.05.018_bib67","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semnephrol.2007.01.009","article-title":"The renin-angiotensin system and diabetic nephropathy","volume":"27","author":"Gurley","year":"2007","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.bcp.2009.05.018_bib68","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/ndt\/gfn377","article-title":"Activation of the renal renin-angiotensin system in diabetes\u2014new concepts","volume":"23","author":"Peti-Peterdi","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bcp.2009.05.018_bib69","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib70","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/diab.28.3.237","article-title":"Hyporeninemic hypoaldosteronism in diabetes mellitus. Studies of the autonomic nervous system's control of renin release","volume":"28","author":"Tuck","year":"1979","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2009.05.018_bib71","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.diabres.2008.09.042","article-title":"Diabetic nephropathy: important pathophysiologic mechanisms","volume":"82","author":"Soldatos","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2009.05.018_bib72","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.diabres.2008.09.027","article-title":"Activated prorenin as a therapeutic target for diabetic nephropathy","volume":"82","author":"Ichihara","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.bcp.2009.05.018_bib73","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/HYPERTENSIONAHA.107.107268","article-title":"The collecting duct is the major source of prorenin in diabetes","volume":"51","author":"Kang","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib74","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/HYPERTENSIONAHA.108.113480","article-title":"Antihypertensive and renoprotective mechanisms of renin inhibition in diabetic rats","volume":"52","author":"Carey","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib75","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1007\/s001250051260","article-title":"Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus","volume":"42","author":"Deinum","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2009.05.018_bib76","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00125-007-0795-9","article-title":"Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats","volume":"50","author":"Kelly","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.bcp.2009.05.018_bib77","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.107.108845","article-title":"Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats","volume":"52","author":"Feldman","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib78","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/ki.2008.68","article-title":"Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes","volume":"73","author":"Persson","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.bcp.2009.05.018_bib79","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2009.05.018_bib80","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/ncpneph0962","article-title":"Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?","volume":"4","author":"Schernthaner","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.bcp.2009.05.018_bib81","first-page":"S203","article-title":"Renin-angiotensin system and renal circulation in clinical congestive heart failure","volume":"20","author":"Dzau","year":"1987","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.bcp.2009.05.018_bib82","series-title":"Brenner & Rector's The Kidnney","first-page":"398","article-title":"Control of extracellular fluid and edema formation","author":"Skorecki","year":"2008"},{"key":"10.1016\/j.bcp.2009.05.018_bib83","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/01.CIR.0000091234.45664.62","article-title":"Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial","volume":"108","author":"Cohn","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2009.05.018_bib84","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14779072.7.1.9","article-title":"The CHARM program: the effects of candesartan for the management of patients with chronic heart failure","volume":"7","author":"McKelvie","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.bcp.2009.05.018_bib85","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.HYP.0000179573.91016.3f","article-title":"Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats","volume":"46","author":"Pilz","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib86","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1161\/HYPERTENSIONAHA.108.116350","article-title":"Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure","volume":"52","author":"Westermann","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2009.05.018_bib87","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1470320308097416","article-title":"Role of renin in heart failure and therapeutic potential of direct renin inhibition","volume":"9","author":"Krum","year":"2008","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.bcp.2009.05.018_bib88","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0002-9149(91)90101-P","article-title":"Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure","volume":"67","author":"Neuberg","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.bcp.2009.05.018_bib89","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1161\/01.CIR.90.6.2748","article-title":"Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition","volume":"90","author":"Kiowski","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2009.05.018_bib90","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ejheart.2007.09.002","article-title":"Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure","volume":"9","author":"Seed","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.bcp.2009.05.018_bib91","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCHEARTFAILURE.107.740704","article-title":"Effects of the oral direct inhibitor aliskiren in patients with symptomatic heart failure","volume":"1","author":"McMurray","year":"2008","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.bcp.2009.05.018_bib92","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003088-200847080-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of aliskiren","volume":"47","author":"Vaidyanathan","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bcp.2009.05.018_bib93","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2125.2004.02160.x","article-title":"Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects","volume":"58","author":"Dieterle","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bcp.2009.05.018_bib94","doi-asserted-by":"crossref","first-page":"527","DOI":"10.5414\/CPP43527","article-title":"Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine","volume":"43","author":"Dieterle","year":"2005","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bcp.2009.05.018_bib95","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1124\/dmd.106.013797","article-title":"Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers","volume":"35","author":"Waldmeier","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.bcp.2009.05.018_bib96","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/0091270008323258","article-title":"Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren","volume":"48","author":"Vaidyanathan","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bcp.2009.05.018_bib97","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1755-5922.2008.00058.x","article-title":"Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects","volume":"26","author":"Vaidyanathan","year":"2008","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.bcp.2009.05.018_bib98","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/MNH.0b013e328040bfab","article-title":"The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology","volume":"16","author":"Nguyen","year":"2007","journal-title":"Curr Opin Nephrol Hypertens"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209004274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295209004274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T08:42:13Z","timestamp":1549615333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295209004274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0006295209004274"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2009.05.018","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}